The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases. What is the current Price Target and Forecast for UNITY Biotechnology (UBX) UNITY Biotechnology (UBX) (Delayed Data from NSDQ) 2.13 USD +0.32 (17.68) Updated 04:00 PM ET. Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Forecast Price target 7.33 0.00 0.00 The 3 analysts offering 1 year price forecasts for UBX have a max estimate of and a min estimate of. On average, they expect the companys stock price to reach 6.50 in the next twelve months. The average price target is 6. Their UBX share price targets range from 4.00 to 10.00. was incorporated in 2009 and is headquartered in South San Francisco, California. 6.00 (209.28 Upside) Based on 3 Wall Street analysts offering 12 month price targets for Unity Biotechnology in the last 3 months. and changed its name to Unity Biotechnology, Inc. Return on equity is forecast to be -108.6 in 3 years. 'UBX' stock predictions are updated every 5 minutes with latest exchange prices by smart technical market analysis. EPS is expected to grow by 15.2 per annum. The company was formerly known as Forge, Inc. Unity Biotechnology is forecast to grow earnings and revenue by 4.5 and 71.3 per annum respectively. Completed enrollment in BEHOLD, the Phase 2 clinical trial of UBX1325 in DME BEHOLD remains on track with 12-week safety and efficacy data anticipated by. Reports First Quarter 2022 Financial Results and Business Updates Globe Newswire - Tue May 10, 2022. It also develops UBX1967 for the treatment of ophthalmologic diseases UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. UBX : 1.8401 (-0.54) UNITY Biotechnology, Inc. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. Unity Biotechnology, Inc.Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Wedbush Downgrades Unity Biotechnology to Neutral From Outperform, Notes Limited Cash Runway, Lack of Other Near-Term Value-Driving Catalysts Trims PT to $2 From $3 North American Morning Briefing : Stock Futures -2. The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. UBX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. enters into A Loan and Security Agreement Announces 48-Week Results from Phase 2 Envision Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration It hasnt even been two years since Upstart ( UPST 2.75) stock reached a pinnacle, with the rare and enviable gain of more than 1,000 from its initial public offering in late 2020. Unity Biotechnology Agrees to Exercise Warrants for $4.38 Million in Gross Proceeds Shares Fall Sector Update: Health Care Stocks Rising Late Afternoon Get the latest UNITY Biotechnology, Inc UBX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. The 5 analysts offering 12-month price forecasts for UNITY Biotechnology Inc have a median target of 6.00, with a high estimate of 10.00. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 View UNITY Biotechnology, Inc UBX investment & stock information. Wedbush Upgrades Unity Biotechnology to Outperform From Neutral, Says Remains in Execution Mode With Advancement of UBX1325 Raises PT to $4 From $2 North American Morning Briefing : Stocks Futures -2. Analysts have been steadily raising their estimates. Doses First Patients in Phase 2 Aspire Study of Ubx1325 in DME This company is expected to earn -0.72 per share for the fiscal year ending December 2022, which represents a year-over-year change of 33.9.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |